-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1677 Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
Hematology Disease Topics & Pathways:
Adult, Diseases, Therapies, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Study Population, Clinically relevant, Lymphoid Malignancies
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)

Marie Maerevoet, MD1*, Joost Vermaat, MD, PhD2, Miguel A. Canales3, René-Olivier Casasnovas, MD4*, Eric Van Den Neste5*, Andre Goy, MD6*, Brian T. Hill, MD, PhD7,8, Catherine Thieblemont, MD, PhD9*, Maria De Fatima De La Cruz10*, Federica Cavallo, MD, PhD11*, George Follows, MD12*, Sylvain Choquet, MD13*, Ronit Gurion, MD14*, Reda Bouabdallah, MD15*, Ulrich Jaeger, MD16, Agnes Nagy, MD17*, John Kuruvilla, MD18, Krzysztof Warzocha, MD19*, Nagesh Kalakonda, MD20*, Paolo Caimi, MD21, Sameer Bakhshi, MD22*, Matthew Ku, MBBS, FRACP, FRCPA23*, Nada Hamad, MD24*, Hendrik Veelken, MD, PhD 2, Ewa Matczak, MD25*, Xiwen Ma25*, Jean-Richard Saint-Martin25*, Jatin J. Shah, MD25*, Michael G. Kauffman, MD, PhD25, Sharon Shacham, PhD, MBA25* and Josée M Zijlstra, MD26*

1Institute Jules Bordet, Brussels, Belgium
2Department of Hematology, Leiden University Medical Center, Leiden, Netherlands
3Hospital Univesitario La Paz, Madrid, Spain
4CHU Dijon, Dijon, FRA
5Cliniques universitaires Saint-Luc, Brussels, BEL
6John Theurer Cancer Center at Hackensack-UMC, Hackensack, NJ
7Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH
8Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Hopital St Louis, Paris, France
10Hospital University Virgen del Rocio, Sevilla, Spain
11University of Torino, Department of Molecular Biotechnologies and Health Sciences, Turin, Italy
12Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge, United Kingdom
13Hospital Pitie Salpetriere, Paris, France
14Rabin Medical Center, Petah Tikva, ISR
15Institut Paoli Calmettes, Department of Hematology, Marseille, France
16Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Medical University of Vienna, Medical University of Vienna, Vienna, AA, Austria
17University of Pécs, ÁOK, Pécs, Hungary
18Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
19Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
20Department of Haematology, Royal Liverpool University Hospital, Liverpool, United Kingdom
21Case Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OH
22Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
23Department of Haematology, St. Vincent's Hospital, Melbourne, Australia
24St. Vincent’s Hospital, Sydney, Australia
25Karyopharm Therapeutics, Newton, MA
26Department of Hematology, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands

Introduction: Patients (pts) with relapsed/refractory (R/R) DLBCL after two or more lines of therapy and who are not candidates for stem cell transplantation have limited effective treatment options and a poor prognosis. Selinexor, an oral XPO1 inhibitor, causes nuclear accumulation and activation of tumor suppressor proteins including p53, p21, and IκBα, along with reductions in c-Myc and Bcl-2 oncogenes. In a phase 1 clinical study (NCT01607892), pts with R/R DLBCL treated with selinexor had an overall response rate (ORR) of 32%, with 4 complete responses (CRs, 6%). Based on these findings, a phase 2b open-label study (SADAL) of selinexor in pts with R/R DLBCL not candidates for transplantation was initiated.

Methods: Pts with R/R DLBCL were stratified by subtype (GCB or non-GCB). Pts achieving a best response of PR/CR on prior therapy required a 8 week washout before enrolling on trial. The primary objectives included efficacy (ORR and associated DOR) and safety.Pts were initially randomized to 60 or 100 mg of selinexor twice weekly (8 doses) per 28-day cycle. Disease response was assessed by an Independent Central Radiological Review (ICRR), using the Lugano Classification (Cheson, 2014).

Results: Preliminary results from the planned interim analysis showed similar ORRs on the 60 and 100 mg doses, but reduced DOR and tolerability at the higher dose; the 100 mg arm was therefore discontinued. 110 pts were enrolled on the 60 mg arm (66 M/ 44 F, median age 67 yrs) with a median of 3 (range 2–5) prior treatment regimens. The most frequently reported treatment related adverse events (AEs) included(all grades, grades 3, 4): nausea (51%, 6%, 0%), fatigue (50%, 10%, 0%), thrombocytopenia (47%, 22%, 15%), anorexia (35%, 2%, 0%), neutropenia (27%, 20%, 0%), and anemia (27%, 12%, 1%). These AEs were managed with dose modifications and/or standard supportive care. At the planned interim analysis (N=32, 60 mg) the ICRR determined ORR was 34.4% (5 CRs and 6 partial responses (PRs)). The median duration of response (DOR) was 8.4 months. ORR was 33.3% in GCB and 35.3% in non-GCB subtypes. The median overall survival (OS) was 9.0 months. Median OS (Figure 1) in pts ≥PR was not reached and was significantly longer vs median OS for pts ≤ stable disease (SD) of 4.1 months (p=<0.001).

Conclusion: Single agent oral selinexor is active in pts with R/R DLBCL across both GCB and non-GCB subtypes. Responses were deep with CRs noted on therapy and durable, with some responses >24 months, consistent with significant clinical benefit. Importantly, response to therapy (≥PR) was associated with significant improvement in OS of 9.0 months vs 4.1 months for those with ≤SD. Enrollment completion is expected by September 2018. Full study results (N=130) will be presented, including longer follow up (DOR and OS) of pts from the original interim analysis. Pts enrolled in SADAL represent an unmet medical need population, and selinexor may help address this need.

Disclosures: Casasnovas: Roche: Consultancy, Research Funding; Merck: Consultancy; Bristol-Meyers Squibb: Consultancy; AbbVie: Consultancy; Takeda: Consultancy; Gilead: Consultancy, Research Funding. Goy: Acerta: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pharmacyclics/J&J: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Hackensack University Medical Center: Employment; Kite/Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Genentech: Research Funding; Seattle Genetics: Research Funding; COTA: Membership on an entity's Board of Directors or advisory committees. Hill: Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Research Funding; Seattle Genetics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees. Follows: Gilead, Janssen, Roche, Abbvie, Takeda, BMS: Membership on an entity's Board of Directors or advisory committees. Jaeger: GSK: Membership on an entity's Board of Directors or advisory committees; Infinity: Membership on an entity's Board of Directors or advisory committees; Bioverativ: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Mundipharma: Membership on an entity's Board of Directors or advisory committees; MSD: Research Funding; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AOP Orphan: Membership on an entity's Board of Directors or advisory committees; Takeda-Millenium: Membership on an entity's Board of Directors or advisory committees; Takeda-Millenium: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Kuruvilla: Karyopharm: Honoraria; Gilead: Consultancy, Honoraria; Celgene: Honoraria; Abbvie: Consultancy; Princess Margaret Cancer Foundation: Research Funding; Roche: Consultancy, Honoraria, Research Funding; Lundbeck: Honoraria; Amgen: Honoraria; Janssen: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria; Leukemia and Lymphoma Society Canada: Research Funding; Seattle Genetics: Consultancy, Honoraria; Merck: Consultancy, Honoraria. Caimi: Kite Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Research Funding; Genentech: Membership on an entity's Board of Directors or advisory committees; Celgene: Speakers Bureau. Matczak: Karyopharm Therpeutics: Employment. Ma: Karyopharm Therapeutics: Employment. Saint-Martin: Karyopharm Therapeutics: Employment. Shah: Karyopharm Therapeutics: Employment. Kauffman: Karyopharm Therapeutics: Employment, Equity Ownership, Membership on an entity's Board of Directors or advisory committees. Shacham: Karyopharm Therapeutics: Employment, Equity Ownership, Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH